Cancer Management and Research (Jul 2021)

Astragalus IV Undermines Multi-Drug Resistance and Glycolysis of MDA-MB-231/ADR Cell Line by Depressing hsa_circ_0001982-miR-206/miR-613 Axis

  • Li H,
  • Xia Z,
  • Liu L,
  • Pan G,
  • Ding J,
  • Liu J,
  • Kang J,
  • Li J,
  • Jiang D,
  • Liu W

Journal volume & issue
Vol. Volume 13
pp. 5821 – 5833

Abstract

Read online

Hongchang Li,1,* Zhihua Xia,2,* Limin Liu,3,* Gaofeng Pan,1 Junbin Ding,1 Jiazhe Liu,1 Jie Kang,1 Jindong Li,1 Daowen Jiang,1 Weiyan Liu1 1Department of General Surgery, Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, 201100, People’s Republic of China; 2Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People’s Republic of China; 3Department of Medical Rehabilitation, Heze Domestic Professional College, Heze, 274300, Shandong, People’s Republic of China*These authors contributed equally to this workCorrespondence: Weiyan Liu; Daowen JiangDepartment of General Surgery, Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, No. 170 Xinsong Road, Shanghai, 201100, People’s Republic of ChinaEmail [email protected]; [email protected]: Allowing for the power of astragalus in improving cancer patients’ response to chemotherapy, we endeavored to clarify if hsa_circ_0001982-centered miRNA axes participated in the impact of astragaloside IV on multi-drug resistance (MDR) of triple-negative breast cancer (TNBC).Methods: TNBC patients were recruited into an Astragalus detoxification decoction (ADD) treatment group (N=62) and a non-ADD treatment group (N=78), according to whether they consumed ADD after chemotherapy or not. Furthermore, drug resistance of the MDA-MB-231/ADR cell line in response to gemcitabine (GEM), adriamycin (ADM), oxaliplatin (OXA), and cisplatin (DDP) was evaluated, and glycolytic potential of MDA-MB-231/ADR cells was determined after astragaloside IV treatment or si-hsa_circ_0001982/miR-206 inhibitor/miR-613 inhibitor transfection.Results: TNBC patients receiving ADD adjuvant therapy after chemotherapy, with decreased serum level of hsa_circ_0001982 and increased serum level of miR-206/miR-613 as relative to non-ADD treatment group (P< 0.05), were less likely to relapse than TNBC population not undergoing ADD treatment (P< 0.05). In addition, GEM/ADM/OXA/DDP-resistance and glycolysis of MDA-MB-231/ADR cell line were debilitated after exposure to astragaloside IV or transfection by si-hsa_circ_0001982 (P< 0.05). Nonetheless, miR-206/miR-613 inhibitor transfection reversed inhibitory effects of si-hsa_circ_0001982 and astragaloside IV on glycolysis and MDR of MDA-MB-231/ADR cell line (P< 0.05).Conclusion: Astragaloside IV undermined MDR and glycolysis of MDA-MB-231/ADR cell line by blocking hsa_circ_0001982-miR-206/miR-613 axis.Keywords: triple-negative breast cancer, astragaloside IV, hsa_circ_0001982, miR-206, miR-613, multi-drug resistance, glycolysis

Keywords